<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments</title>
  </titleInfo>
  <name type="personal">
    <namePart>Gunjan Dagar</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ashna Gupta</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Tariq Masoodi</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sabah Nisar</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Maysaloun Merhi</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sheema Hashem</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ravi Chauhan</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Manisha Dagar</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Sameer Mirza</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Puneet Bagga</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Rakesh Kumar</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Ammira S Al-Shabeeb Akil</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Review articles.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">xx</placeTerm>
    </place>
    <dateIssued encoding="marc">2023</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>1 online resource (1 article).</extent>
  </physicalDescription>
  <abstract>Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune system's T-cells to recognize and attack tumor cells. T-cells are isolated from patients and modified to target tumor-associated antigens. CAR-T therapy has achieved FDA approval for treating blood cancers like B-cell acute lymphoblastic leukemia, large B-cell lymphoma, and multiple myeloma by targeting CD-19 and B-cell maturation antigens. Bi-specific chimeric antigen receptors may contribute to mitigating tumor antigen escape, but their efficacy could be limited in cases where certain tumor cells do not express the targeted antigens. Despite success in blood cancers, CAR-T technology faces challenges in solid tumors, including lack of reliable tumor-associated antigens, hypoxic cores, immunosuppressive tumor environments, enhanced reactive oxygen species, and decreased T-cell infiltration. To overcome these challenges, current research aims to identify reliable tumor-associated antigens and develop cost-effective, tumor microenvironment-specific CAR-T cells. This review covers the evolution of CAR-T therapy against various tumors, including hematological and solid tumors, highlights challenges faced by CAR-T cell therapy, and suggests strategies to overcome these obstacles, such as utilizing single-cell RNA sequencing and artificial intelligence to optimize clinical-grade CAR-T cells.</abstract>
  <note type="statement of responsibility">Gunjan Dagar; Ashna Gupta; Tariq Masoodi [and others].</note>
  <note>The source lists 17 contributors; the first 12 names are recorded as access points. The complete source author list is retained in the catalogue manifest.</note>
  <note>Publication type: Review article.</note>
  <note>Linked open-access copy: published version.</note>
  <note>Open access; no subscription required for the linked open-access version. Unrestricted online access star</note>
  <note xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution. See the linked licence for the applicable terms. https://creativecommons.org/licenses/by/4.0/</note>
  <note>In English.</note>
  <subject>
    <topic>Tumor antigens</topic>
  </subject>
  <subject>
    <topic>Immunotherapy</topic>
  </subject>
  <subject>
    <topic>Hematological malignancy</topic>
  </subject>
  <subject>
    <topic>Solid tumor</topic>
  </subject>
  <subject>
    <topic>Cytokine Release Syndrome</topic>
  </subject>
  <subject>
    <topic>Antigen Escape</topic>
  </subject>
  <subject>
    <topic>B. Sc. Medical Laboratory Science</topic>
  </subject>
  <subject>
    <topic>UMUN open access collection</topic>
  </subject>
  <subject>
    <topic>hematology</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>Journal of translational medicine</title>
    </titleInfo>
    <identifier type="issn">1479-5876</identifier>
    <part>
      <text>Vol. 21, no. 1, (2023), pages/article 449</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://europepmc.org/articles/PMC10327392</identifier>
  <location>
    <url displayLabel="Read open-access publication">https://europepmc.org/articles/PMC10327392</url>
  </location>
  <accessCondition type="restrictionOnAccess">Open access; no subscription required for the linked open-access version.</accessCondition>
  <accessCondition type="useAndReproduction">Creative Commons Attribution. See the linked licence for the applicable terms.</accessCondition>
  <recordInfo>
    <recordContentSource authority="marcorg">local</recordContentSource>
    <recordCreationDate encoding="marc">261005</recordCreationDate>
    <recordChangeDate encoding="iso8601">20261005174904.0</recordChangeDate>
    <recordIdentifier source="local">UMUN-OA-20261005-MLS-032</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
